本文選題：B群鏈球菌　切入點：FbsA　出處：《北京生物制品研究所》2008年碩士論文

【摘要】： B群鏈球菌(GBS)是新生兒感染的重要原因,可引起新生兒肺炎.敗血癥和腦膜炎,同時也可引起免疫功能低下的成年人的蜂窩組織炎、關節(jié)炎、心內膜炎及尿路感染等。GBS疫苗的發(fā)展主要經(jīng)歷了莢膜多糖疫苗、莢膜多糖—蛋白結合疫苗兩個階段,現(xiàn)在正在研究蛋白疫苗。目前,GBS的許多表面蛋白被相繼發(fā)現(xiàn),蛋白疫苗、多價蛋白疫苗有望成為控制GBS感染的疫苗。FbsA是能夠與人纖維蛋白原結合的GBS表面蛋白,被認為是GBS的重要侵襲因子,與GBS侵入粘膜上皮細胞、血小板凝集、抗吞噬細胞的吞噬及免疫逃逸等有關。所以FbsA有可能成為有效阻止GBS感染的蛋白疫苗。本實驗通過獲取GBSⅢ型32325株表面蛋白,再通過等電沉淀法,聚丙烯酸沉淀法和凝膠過濾純化獲得GBS表面蛋白FbsA。并通過合成FbsA的重復16肽GNVLERRQRDAENRSQ再與牛血清白蛋白偶聯(lián)所形成的抗原免疫家兔獲得抗血清鑒定所純化的抗原。將純化的FbsA以不同劑量和針次免疫NIH小鼠,用間接ELISA法檢測小鼠血清抗體的滴度。結果表明,5μg免疫3次可獲得較高的抗體滴度且有免疫記憶。在此基礎上,初步探討了抗FbsA血清的中和作用。
[Abstract]:Group B streptococcus is an important cause of neonatal infection, causing neonatal pneumonia, septicemia and meningitis, as well as cellulitis and arthritis in adults with low immune function. The development of GBS vaccine, such as endocarditis and urinary tract infection, mainly went through two stages of capsule polysaccharide vaccine and capsule polysaccharide protein-binding vaccine. Now protein vaccine is being studied. At present, many surface proteins of GBS have been discovered one after another, protein vaccine. Multivalent protein vaccine is expected to be a vaccine to control GBS infection. FbsA is a surface protein of GBS that can bind to human fibrinogen. It is considered to be an important invading factor of GBS. It is associated with GBS invasion of mucosal epithelial cells and platelet agglutination. Therefore, FbsA may be an effective protein vaccine to prevent GBS infection. In this study, the surface proteins of 32325 strains of GBS type 鈪，

本文編號：1690330